GPP
NGNE icon

Great Point Partners’s Neurogene NGNE Stock Holding History

Great Point Partners’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.1M Sell
352,180
-147,820
-30% -$4.07M 2.09% 20
2026
Q1 		$10.1M Buy
500,000
+150,000
+43% +$2.91M 2.32% 16
2025
Q4 		$7.21M Sell
350,000
-96,814
-22% -$2.41M 2.34% 17
2025
Q3 		$7.74M Sell
446,814
-39,045
-8% -$784K 3.19% 13
2025
Q2 		$7.26M Buy
485,859
+14,895
+3% +$234K 4.72% 6
2025
Q1 		$5.51M Buy
470,964
+28,203
+6% +$490K 2.92% 15
2024
Q4 		$10.1M Sell
442,761
-561,530
-56% -$20.9M 4.77% 8
2024
Q3 		$42.1M Hold
1,004,291
– – 12.4% 1
2024
Q2 		$36.5M Hold
1,004,291
– – 7% 2
2024
Q1 		$51.1M Buy
1,004,291
+10,062
+1% +$336K 7.97% 1
2023
Q4 		$19.3M Buy
+994,229
New +$14.2M 3.28% 14
2020
Q3 		– Sell
-703
Closed -$233K – 39
2020
Q2 		$233K Sell
703
-1,314
-65% -$343K 0.02% 36
2020
Q1 		$459K Buy
+2,017
New +$415K 0.05% 36
2015
Q4 		– Sell
-5,000
Closed -$1.41M – 26
2015
Q3 		$1.41M Buy
+5,000
New +$1.15M 0.56% 29

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Great Point Partners's NGNE Position: Q2 2026 in Review

Great Point Partners reduced its Neurogene (NGNE) stake by 30% in Q2 2026, selling an estimated $4.07M and leaving 352,180 shares worth $11.1M. The position accounts for 2.09% of the portfolio, ranked #20.

Great Point Partners first reported a position in NGNE in Q3 2015 and has held it in 14 quarters since. The position peaked at $51.1M in Q1 2024. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Great Point Partners held 352,180 shares of Neurogene worth $11.1M as of Q2 2026.
  • Great Point Partners sold 147,820 Neurogene shares in Q2 2026, an estimated $4.07M.
  • Neurogene made up 2.09% of Great Point Partners's portfolio in Q2 2026, its #20 holding.
  • Great Point Partners first reported a position in Neurogene in Q3 2015 and has held it in 14 quarters since.
  • Great Point Partners's Neurogene position peaked at $51.1M in Q1 2024.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.